selected publications
-
Influencing the Tumor Microenvironment: A Phase II Study of Copper Depletion Using Tetrathiomolybdate in Patients with Breast Cancer at High Risk for Recurrence and in Preclinical Models of Lung Metastases.
Clinical cancer research : an official journal of the American Association for Cancer Research.
2016
Academic Article
GET IT
Times cited: 109 -
Pro1170 Ala polymorphism in HER2-neu is associated with risk of trastuzumab cardiotoxicity.
BMC cancer.
2015
Academic Article
GET IT
Times cited: 54 -
Phase II trial of bortezomib alone or in combination with irinotecan in patients with adenocarcinoma of the gastroesophageal junction or stomach.
Investigational new drugs.
2014
Academic Article
GET IT
Times cited: 11 -
Tetrathiomolybdate-associated copper depletion decreases circulating endothelial progenitor cells in women with breast cancer at high risk of relapse.
Annals of oncology : official journal of the European Society for Medical Oncology.
2013
Academic Article
GET IT
Times cited: 67 -
Overcoming the response plateau in multiple myeloma: a novel bortezomib-based strategy for secondary induction and high-yield CD34+ stem cell mobilization.
Clinical cancer research : an official journal of the American Association for Cancer Research.
2013
Academic Article
GET IT
Times cited: 19 -
Incremental increase in VEGFR1⁺ hematopoietic progenitor cells and VEGFR2⁺ endothelial progenitor cells predicts relapse and lack of tumor response in breast cancer patients.
Breast cancer research and treatment.
2011
Academic Article
GET IT
Times cited: 30 -
Phase II trial of the ribonucleotide reductase inhibitor 3-aminopyridine-2-carboxaldehydethiosemicarbazone plus gemcitabine in patients with advanced biliary tract cancer.
Cancer chemotherapy and pharmacology.
2010
Academic Article
GET IT
Times cited: 22